Alemtuzumab (Anti-CD52 mAb) Induces Expansion of Treg and Th2 Cells and Inhibits Th1 and Th17 Cells in Treated Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (P02.119)
Neurology(2012)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Neurology(2012)